Survodutide vs DSIP
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideSleep OptimizationCognitive Enhancement
DSIP- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
- Half-Life
- ~7 days
- ~30–60 minutes; however downstream sleep effects last 4–6 hours
- Admin Route
- SubQ
- SubQ, IV, Intranasal
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 100–400 mcg
- Frequency
- Once weekly
- Once nightly
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Induces and deepens delta-wave (slow-wave) sleep
- Reduces cortisol and normalizes HPA axis
- Improves sleep quality in insomnia patients
- Anti-stress and anxiolytic effects
- May improve opiate/alcohol withdrawal symptoms
- Analgesic properties through opioid modulation
- Antioxidant and neuroprotective effects
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Generally well tolerated
- Mild grogginess next morning at higher doses
- Rare: hypotension
- Potential for altered dream patterns
- Stacks With
- —
- —